Glycemic Control and Excess Mortality in Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The excess risk of death from any cause and of death from cardiovascular causes is unknown among patients with type 1 diabetes and various levels of glycemic control. We conducted a registry-based observational study to determine the excess risk of death according to the level of glycemic control in a Swedish population of patients with diabetes. METHODS: We included in our study patients with type 1 diabetes registered in the Swedish National Diabetes Register after January 1, 1998. For each patient, five controls were randomly selected from the general population and matched according to age, sex, and county. Patients and controls were followed until December 31, 2011, through the Swedish Register for Cause-Specific Mortality. RESULTS: The mean age of the patients with diabetes and the controls at baseline was 35.8 and 35.7 years, respectively, and 45.1% of the participants in each group were women. The mean follow-up in the diabetes and control groups was 8.0 and 8.3 years, respectively. Overall, 2701 of 33,915 patients with diabetes (8.0%) died, as compared with 4835 of 169,249 controls (2.9%) (adjusted hazard ratio, 3.52; 95% confidence interval [CI], 3.06 to 4.04); the corresponding rates of death from cardiovascular causes were 2.7% and 0.9% (adjusted hazard ratio, 4.60; 95% CI, 3.47 to 6.10). The multivariable-adjusted hazard ratios for death from any cause according to the glycated hemoglobin level for patients with diabetes as compared with controls were 2.36 (95% CI, 1.97 to 2.83) for a glycated hemoglobin level of 6.9% or lower (≤52 mmol per mole), 2.38 (95% CI, 2.02 to 2.80) for a level of 7.0 to 7.8% (53 to 62 mmol per mole), 3.11 (95% CI, 2.66 to 3.62) for a level of 7.9 to 8.7% (63 to 72 mmol per mole), 3.65 (95% CI, 3.11 to 4.30) for a level of 8.8 to 9.6% (73 to 82 mmol per mole), and 8.51 (95% CI, 7.24 to 10.01) for a level of 9.7% or higher (≥83 mmol per mole). Corresponding hazard ratios for death from cardiovascular causes were 2.92 (95% CI, 2.07 to 4.13), 3.39 (95% CI, 2.49 to 4.61), 4.44 (95% CI, 3.32 to 5.96), 5.35 (95% CI, 3.94 to 7.26), and 10.46 (95% CI, 7.62 to 14.37). CONCLUSIONS: In our registry-based observational study, patients with type 1 diabetes and a glycated hemoglobin level of 6.9% or lower had a risk of death from any cause or from cardiovascular causes that was twice as high as the risk for matched controls. (Funded by the Swedish Society of Medicine and others.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These diseases represent the first cause of mortality even for those who achieve optimal glycemic control.140”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [140]
In the citing paper
“Improving glycaemic control is of importance due to the excess risk of mortality in those with poor glycaemic control.44”
From Acceptance and commitment therapy (ACT) for adult type 1 diabetes management: Study protocol for a randomised controlled trial (2018) · cites this paper as [44]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Wettermark, B., Hammar, N., MichaelFored, C., Leimanis, A., Otterblad Olausson, P., Bergman, U., Persson, I., Sundström, A., Westerholm, B., & Rosén, M. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1294 · Cited by 1,887
Booth, G., & Cheng, A. Y. Y. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.010 · Cited by 1,220
Cheng, A. Y. Y. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.009 · Cited by 728
Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes
Laing, S. P., Swerdlow, A. J., Slater, S. D., Burden, A. C., Morris, A., Waugh, N. R., Gatling, W., Bingley, P. J., & Patterson, C. C. (2003) · Diabetologia · doi:10.1007/s00125-003-1116-6 · Cited by 724
The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes
Groop, P.-H., Thomas, M. C., Moran, J. L., Wadèn, J., Thorn, L. M., Mäkinen, V.-P., Rosengård-Bärlund, M., Saraheimo, M., Hietala, K., Heikkilä, O., et al. (2009) · Diabetes · doi:10.2337/db08-1543 · Cited by 638
Laing, S. P., Swerdlow, A. J., Slater, S. D., Botha, J. L., Burden, A. C., Waugh, N. R., Smith, A. W. M., Hill, R. D., Bingley, P. J., Patterson, C. C., et al. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00075.x · Cited by 425
Research works printed but not linked: 1
- Parving HH, Mauer M, Ritz E. Diabetic nephropathy. In: Brenner BM, ed. Brenner and Rector’s the kidney, 7th ed. Philadelphia: WB Saunders, 2004:1777-1818.
Cited by
Items 401–500 of 963
Kiss, Z., Rokszin, G., Abonyi‐Tóth, Z., Jermendy, G., Kempler, P., Barkai, L., & Wittmann, I. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3190 · Cited by 16
Petria, I., Albuquerque, S., Varoquaux, G. P., Vie, J.-J., Venteclef, N., Mohammedi, K., Roussel, R., Camoin, M., Perseghin, G., Velho, G., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01689-0 · Cited by 14
Glycaemic control and sepsis risk in adults with type 1 diabetes
Balintescu, A., Lind, M., Andersson, M., Oldner, A., Cronhjort, M., Eliasson, B., Svensén, C., & Mårtensson, J. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15060 · Cited by 15
Self-citationBuchmann, M., Tuncer, O., Auzanneau, M., Eckert, A. J., Rosenbauer, J., Reitzle, L., Heidemann, C., Holl, R. W., & Thamm, R. (2023) · PubMed Central · doi:10.25646/11439 · Cited by 30
Giménez‐Pérez, G., Viñals, C., Mata‐Cases, M., Vlacho, B., Real, J., Franch‐Nadal, J., Ortega, E., & Mauricio, D. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01917-1 · Cited by 15
“Background Cardiovascular disease (CVD) is the main cause of morbidity and mortality among people with type 1 diabetes (T1D), even in those with good metabolic control [1, 2].”
BackgroundSerés‐Noriega, T., Perea, V., & Amor, A. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13041097 · Cited by 17
“Hyperglycaemia is one of the most important CVR factors; however, even those with optimal glycaemic control (time-updated haemoglobin A1c (HbA1c) ≤ 6.9% or 51.9 mmol/mol) have a three-fold increased risk of CVD death compared with their counterparts without diabetes [19].”
BackgroundInfluentialKosteria, I., Schwandt, A., Davis, E. A., Jali, S. M., Prieto, M., Rottembourg, D., & the SWEET study group (2019) · Diabetic Medicine · doi:10.1111/dme.13963 · Cited by 18
Treatment strategies for hypertension in patients with type 1 diabetes
Katsimardou, A., Imprialos, K. P., Stavropoulos, K., Sachinidis, A. G., Doumas, M. N., & Athyros, V. G. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1729124 · Cited by 17
“T1DM individuals share an increased risk for cardiovascular disease (CVD), which translates into increased morbidity and mortality compared to healthy controls [7,8] This fact highlights the need for better management of all the possible risk factors that can affect CVD progression, such as arterial hypertension, whic…”
BackgroundSchnell, O., Valensi, P. E., Standl, E., & Ceriello, A. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.129 · Cited by 15
Ólafsdóttir, A. F., Bolinder, J., Heise, T., Polonsky, W. H., Ekelund, M., Wijkman, M., Pivodic, A., Ahlén, E., Schwarcz, E., Nyström, T., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14257 · Cited by 14
“It has also been shown to reduce excess risk of mortality.(4,5) Many people with type 1 diabetes struggle to keep blood glucose at acceptable levels while avoiding periods of hypoglycaemia.”
BackgroundSelf-citationSurvival of children and youth with type 1 diabetes mellitus in Tanzania
Majaliwa, E., Minja, L., Ndayongeje, J., Ramaiya, K. L., Mfinanga, S., & Mmbaga, B. T. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13425 · Cited by 14
Decreased eGFR as a Risk Factor for Heart Failure in 13 781 Individuals With Type 1 Diabetes
Vestberg, D., Rosengren, A., Olsson, M., Guðbjörnsdóttir, S., Haraldsson, B. S., Svensson, A., & Lind, M. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815596174 · Cited by 16
Self-citationPancreatic Islet Transplantation Technologies: State of the Art of Micro- and Macro-Encapsulation
Cantarelli, E., Citro, A., & Piemonti, L. (2017) · Current Transplantation Reports · doi:10.1007/s40472-017-0154-9 · Cited by 14
Ahola, A. J., Harjutsalo, V., Forsblom, C. M., Freese, R., Mäkimattila, S., & Groop, P. (2017) · Journal of Probiotics & Health · doi:10.4172/2329-8901.1000188 · Cited by 15
Dyslipidaemia in Type 1 Diabetes: Molecular Mechanisms and Therapeutic Opportunities
O’Brien, S. T., Neylon, O. M., & O’Brien, T. (2021) · Biomedicines · doi:10.3390/biomedicines9070826 · Cited by 18
Eliasson, B., Lyngfelt, L., Strömblad, S.-O., Franzén, S., & Eeg‐Olofsson, K. (2022) · Scientific Reports · doi:10.1038/s41598-022-22932-4 · Cited by 20
Isaksson, S. S., Ólafsdóttir, A. F., Ivarsson, S., Imberg, H., Toft, E., Hallström, S., Rosenqvist, U., Ekström, M., & Lind, M. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100799 · Cited by 23
Self-citationSingh, R., Imberg, H., Ahmadi, S. S., Hallström, S., JENDLE, J. H., Tengmark, B.-O., Folino, A., Marie, E., & Lind, M. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241242386 · Cited by 17
Self-citationYakubu, T., Pawer, S., West, N., Tang, T. S., & Görges, M. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01560-4 · Cited by 17
Sechterberger, M. K., van Steen, S. C. J., Boerboom, E. M. N., van der Voort, P. H. J., Bosman, R. J., Hoekstra, J. B. L., & DeVries, J. H. (2016) · Journal of Critical Care · doi:10.1016/j.jcrc.2016.12.021 · Cited by 17
Closed-loop insulin delivery systems in children and adolescents with type 1 diabetes
Dovč, K., & Battelino, T. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1713747 · Cited by 15
Nelson, A. S., Maddaloni, M., Abbott, J. R., Hoffman, C. A., Akgül, A., Ohland, C., Gharaibeh, R. Z., Jobin, C., Brusko, T. M., & Pascual, D. W. (2020) · Scientific Reports · doi:10.1038/s41598-020-62881-4 · Cited by 14
Fagninou, A., Nekoua, M. P., Sossou, D., Moutairou, K. A., Fiévet, N., & Yessoufou, A. (2020) · Journal of Immunology Research · doi:10.1155/2020/2038746 · Cited by 15
Armario, P., Brotons, C., Elosúa, R., de Leciñana, M. A., Castro, A., Clarà, A. B. I., Cortés, O., Rodríguez, Á. D., Herranz, M., Justo, S., et al. (2020) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2020.07.004 · Cited by 15
Immunogenicity of β-cells for autologous transplantation in type 1 diabetes
Schuetz, C., & Markmann, J. F. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.03.003 · Cited by 15
Etet, P. F. S., Farahna, M., Satti, G. M. H., Bushara, Y. M., El-Tahir, A., Hamza, M. A., Osman, S. Y., Dibia, A. C., & Vecchio, L. (2017) · Journal of Complementary and Integrative Medicine · doi:10.1515/jcim-2016-0167 · Cited by 13
Miller, R. G., & Costacou, T. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1240-4 · Cited by 16
Chepulis, L. M., Tamatea, J. A. U., Wang, C., Goldsmith, J., Mayo, C., & Paul, R. G. (2021) · Internal Medicine Journal · doi:10.1111/imj.14816 · Cited by 15
Twigg, S. M., & Wong, J. (2015) · The Medical Journal of Australia · doi:10.5694/mja14.01234 · Cited by 14
Vergani, M., Borella, N. D., Rizzo, M., Conti, M., Perra, S., Bianconi, E., Sani, E., Csermely, A., Grespan, E., Targher, G., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16333 · Cited by 16
“13 Whether and to what extent chronic hyperglycaemia, glycaemic variability and insulin resistance may impact hepatic steatosis and fibrosis in adult patients with T1DM is currently uncertain.”
STOUGAARD, E. B., Andersen, M. R., Bagger, J. I., Søndergaard, E., Østergaard, J. A., Curovic, V. R., Persson, F., Almdal, T., Mathiesen, A. S., Andries, A., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16606 · Cited by 14
Glyoxalase 1 knockdown induces age‐related β‐cell dysfunction and glucose intolerance in mice
Prevenzano, I., Leone, A., Longo, M., Nicolò, A., Cabaro, S., Collina, F., Panarese, I., Botti, G., Formisano, P., Napoli, R., et al. (2022) · EMBO Reports · doi:10.15252/embr.202152990 · Cited by 13
Michels, A. W., Brusko, T. M., Evans‐Molina, C., Homann, D., Richardson, S. J., & Powers, A. C. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf267 · Cited by 18
Sivasubramaniyam, S., Amiel, S. A., & Choudhary, P. (2017) · Diabetic Medicine · doi:10.1111/dme.13438 · Cited by 12
Ruiz, S., Amor, A. J., Pané, A., Andújar, A. M., Montagud‐Marrahí, E., Ventura‐Aguiar, P., Ferrer, J., & Esmatjes, E. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108135 · Cited by 13
Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review
Hropot, T., Battelino, T., & Dovč, K. (2022) · Hormone Research in Paediatrics · doi:10.1159/000527653 · Cited by 12
Insulin resistance is more frequent in type 1 diabetes patients with long disease duration
Xie, Y., Shi, M., Ji, X., Huang, F., Li, F., Li, X., & Zhou, Z. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3640 · Cited by 15
Corpeleijn, W. E., de Waal, W. J., Schipper, H. S., & Wiegman, A. (2023) · Diabetologia · doi:10.1007/s00125-023-06041-z · Cited by 16
van Beers, C. A. J., Kleijer, S. J., Serné, E. H., Geelhoed-Duijvestijn, P. H. L. M., Snoek, F. J., Kramer, M. H. H., & Diamant, M. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0040-3 · Cited by 14
Epidemiología en la diabetes tipo 1: ayudando a encajar las piezas del puzle
Forga, L. (2015) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2015.02.002 · Cited by 35
Nyström, T., Holzmann, M. J., & Sartipy, U. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002411 · Cited by 13
Sarwar, K., Cliff, P., Saravanan, P., Khunti, K., Nirantharakumar, K., & Narendran, P. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-015005 · Cited by 13
Knorr, S., Juul, S., Bytoft, B., Lohse, Z., Clausen, T. D., Jensen, R. B., Damm, P., Beck‐Nielsen, H., Mathiesen, E. R., Jensen, D. M., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4575-5 · Cited by 17
Risk factors for decline in renal function among young adults with type 1 diabetes
Schwandt, A., Bergis, D., Denkinger, M. D., Gollisch, K. S. C., Sandig, D., Stingl, H., Zimny, S., & Holl, R. W. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.07.007 · Cited by 12
Nerpin, E., Toft, E., Fischier, J., Olinder, A. L., & Leksell, J. K. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00615-3 · Cited by 16
Melin, E. O., Dereke, J., & Hillman, M. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01397-2 · Cited by 13
Shi, M., Tang, R., Huang, F., Zhong, T., Chen, Y., Li, X., & Zhou, Z. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3423 · Cited by 15
Lee, Y., Kim, B., Park, J., Kim, M., Choi, M. S., Kim, G., Jin, S., Hur, K. Y., Han, K., & Kim, J. H. (2021) · International Journal of Obesity · doi:10.1038/s41366-021-00922-2 · Cited by 13
Kekäläinen, P., Tirkkonen, H., & Laatikainen, T. K. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.03.005 · Cited by 14
Tanenbaum, M. L., Pang, E., Tam, R., Bishop, F. K., Prahalad, P., Zaharieva, D. P., Addala, A., Wong, J. J., Naranjo, D. M., Hood, K. K., et al. (2024) · Diabetic Medicine · doi:10.1111/dme.15423 · Cited by 13
Cardiovascular Risk Prediction Scores in Type 1 Diabetes
Erqou, S. A., Shahab, A., Fayad, F. H., Haji, M. S., Yuyun, M. F., Joseph, J., Wu, W., Adler, A., Orchard, T. J., & Echouffo-Tcheugui, J. B. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101462 · Cited by 13
Puig-Jové, C., Viñals, C., Conget, I., Quirós, C., Vinagre, I., Berrocal, B., Blanco, J., Granados, M., Mesa, A., Serés‐Noriega, T., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02637-4 · Cited by 14
Persson, E., Persson, S., Gerdtham, U., Carlsson, K. S., & for the Swedish Childhood Diabetes Study Group (2018) · Applied Economics · doi:10.1080/00036846.2018.1558347 · Cited by 15
“Type 1 diabetes is also associated with long-term complications, including cardiovascular disease and nerve, kidney, and eye disease (The Diabetes Control and Complications Trial Research Group 1993; Nathan et al. 2005), as well as mortality risk (Lind et al. 2014; Rawshani et al. 2015).”
BackgroundCooper, J. G., Bakke, Å., Dalen, I., Carlsen, S., Skeie, S., Løvaas, K. F., Sandberg, S., & Thue, G. (2019) · Diabetic Medicine · doi:10.1111/dme.14123 · Cited by 12
Burden of Cardiovascular Disease in Adult Patients with Type 1 Diabetes in the US
Edelman, S. V., Zhou, F. L., Preblick, R., Verma, S., Paranjape, S., Davies, M. J., & Joish, V. N. (2020) · PharmacoEconomics - Open · doi:10.1007/s41669-019-00192-9 · Cited by 11
“Very poor glycemic control has been associated with a tenfold-increased risk of death from cardiovascular disease (CVD) in type 1 diabetes (T1D) compared with the general population [1].”
BackgroundLu, C., Chang, Y., Martini, S., Chang, M., & Li, C. (2020) · Journal of Epidemiology · doi:10.2188/jea.je20200026 · Cited by 16
Melin, E. O., Dereke, J., & Hillman, M. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00727-3 · Cited by 11
Sudden Cardiac Death in Patients With Type 1 Versus Type 2 Diabetes
Norby, F. L., Reinier, K., Uy‐Evanado, A., Nichols, G. A., Stecker, E. C., Jui, J., & Chugh, S. S. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.05.021 · Cited by 12
Ehrmann, D., Chatwin, H., SCHMITT, A. J., Søholm, U., Kulzer, B., Axelsen, J. L., Broadley, M. M., Haak, T., Pouwer, F., & Hermanns, N. (2023) · Diabetic Medicine · doi:10.1111/dme.15040 · Cited by 12
Karmali, R., Sipko, J., Majid, M., & Bruemmer, D. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01866-x · Cited by 11
Bombaci, B., Passanisi, S., Pecoraro, M., Sorrenti, L., Papa, M., Salzano, G., & Lombardo, F. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02245-w · Cited by 12
The 13C Glucose Breath Test Accurately Identifies Insulin Resistance in People With Type 1 Diabetes
Mertens, J., Roosens, L., Braspenning, R., Vandebeeck, J., Francque, S., & Block, C. E. M. D. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae175 · Cited by 10
Advances in Local Drug Release and Scaffolding Design to Enhance Cell Therapy for Diabetes
Bowers, D. T., Botchwey, E. A., & Brayman, K. L. (2015) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2015.0275 · Cited by 11
Silvério, R. N. C., Lacerda, E. M. D. A., Fortins, R. F., de Lima, G. C. F., Scancetti, L. B., do Carmo, C. N., da Cunha, L. V. S., Luescher, J. L., & Padilha, P. D. C. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.06.005 · Cited by 13
Epicardial adipose thickness in youth with type 1 diabetes
Chambers, M. A., Shaibi, G. Q., KAPADIA, C. R., Wyst, K. B. V., Campos, A., Pimentel, J. L., Gonsalves, R., Sandweiss, B. M., & Olson, M. L. (2019) · Pediatric Diabetes · doi:10.1111/pedi.12893 · Cited by 11
“cardiovascular disease (CVD) related death compared to their nondiabetic peers, and this increased risk manifests earlier in life.(1,2)”
BackgroundTancredi, M., Rosengren, A., Svensson, A., Pivodic, A., Guðbjörnsdóttir, S., Wedel, H., & Lind, M. (2019) · Open Heart · doi:10.1136/openhrt-2018-000967 · Cited by 14
Self-citationBertachi, A. H., Biagi, L., Beneyto, A., & Vehí, J. (2020) · Journal of Healthcare Engineering · doi:10.1155/2020/1414597 · Cited by 15
“Subjects with absence of insulin in the body face very high levels of blood glucose (BG) (hyperglycemia), which can lead to long-term micro- and macrovascular complications [1, 2].”
BackgroundMass cytometry and type 1 diabetes research in the age of single-cell data science
Rahman, A. H., & Homann, D. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000549 · Cited by 13
“All rights rese treatment, long-term complications, such as kidney failure, heart attack, and stroke remain a serious challenge to health and well being [1,2,7].”
BackgroundMelin, E. O., Dereke, J., & Hillman, M. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02977-3 · Cited by 11
Rodbard, H. W., Giaccari, A., Cariou, B., Garg, S. K., Davies, M. J., Seth, K., & Sawhney, S. (2021) · Diabetes and Vascular Disease Research · doi:10.1177/1479164121995928 · Cited by 12
Mesa, A., Cofán, M., Esmatjes, E., Perea, V., Boswell, L., Giménez, M., Sala‐Vila, A., Vinagre, I., Viñals, C., Chiva‐Blanch, G., et al. (2021) · European Journal of Nutrition · doi:10.1007/s00394-021-02611-2 · Cited by 11
Boswell, L., Serés‐Noriega, T., Mesa, A., Perea, V., Pané, A., Viñals, C., Blanco, J., Giménez, M., Vinagre, I., Esmatjes, E., et al. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01959-z · Cited by 12
Sanchez, M., Kannengiesser, C., Hoang, S., Potier, L., Fumeron, F., Venteclef, N., Scheen, A. J., Gautier, J., Hadjadj, S., Marre, M., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01635-0 · Cited by 15
Epidemiology of cardiometabolic multiple long-term conditions
Khunti, K., Zaccardi, F., Mehta, R., Gregg, E. W., & Misra, S. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00606-9 · Cited by 17
Glycemic control of adult patients with type 1 diabetes mellitus in Arabian Gulf Countries; PREDICT
Hafidh, K., & Abdella, N. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-00946-3 · Cited by 11
Burckhardt, M., Auzanneau, M., Rosenbauer, J., Binder, E. B., Weiskorn, J., Hess, M., Klinkert, C., Mirza, J., Zehnder, L.-S., Wenzel, S., et al. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241288870 · Cited by 11
Mesa, A., Franch‐Nadal, J., Navas, E., & Mauricio, D. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02791-9 · Cited by 16
Liakopoulos, V., Franzén, S., Svensson, J., Zethelius, B., Ottosson, J., Näslund, I., Guðbjörnsdóttir, S., & Eliasson, B. (2017) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000386 · Cited by 11
Collier, A., Connelly, P. J., Hair, M. D., Cameron, L., Ghosh, S. K., & Waugh, N. R. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13334 · Cited by 12
Caspase 3/ROCK1 pathway mediates high glucose-induced platelet microparticles shedding
Wang, G. H., Ma, K. L., Zhang, Y., Hu, Z. B., Liu, L., Lü, J., Chen, P. P., Lu, C., Ruan, X. Z., & Liu, B. C. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.12.166 · Cited by 11
Ibfelt, E. H., Vistisen, D., Rønn, P. F., Pörksen, S., Madsen, M., Kremke, B., & Svensson, J. (2020) · Diabetic Medicine · doi:10.1111/dme.14401 · Cited by 10
Dena, M., Svensson, A., Eeg-Olofson, K., Young, L., Carlson, A. L., Miller, K. M., Grimsmann, J. M., Welp, R., Mader, J. K., Maahs, D. M., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01169-w · Cited by 15
Self-citationNyström, T., Schwarz, E., Dahlqvist, S., Wijkman, M. O., Ekelund, M., Holmer, H., Bolinder, J., Hellman, J., Imberg, H., Hirsch, I. B., et al. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221101916 · Cited by 11
Self-citationGlycaemia and cardiac arrhythmias in people with type 1 diabetes: A prospective observational study
Hagelqvist, P. G., Andersen, A., Maytham, K. B., Andreasen, C. R., Engberg, S., Lindhardt, T. B., Forman, J. L., Pedersen‐Bjergaard, U., Knop, F. K., & Vilsbøll, T. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15108 · Cited by 16
GAD65: a prospective vaccine for treating Type 1 diabetes?
Ludvigsson, J. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1328495 · Cited by 10
Carpentier, C., Dubois, S. G., Mohammedi, K., Belhatem, N., Bouhanick, B., Rohmer, V., Briet, C., Bumbu, A., Hadjadj, S., Roussel, R., et al. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy197 · Cited by 13
Couper, J., Jones, T. W., Chee, M., Barrett, H. L., Bergman, P. B., Cameron, F. J., Craig, M. E., Colman, P. G., Davis, E. E., Donaghue, K. C., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa727 · Cited by 11
Feingold, K. R. (2020) · Europe PMC (PubMed Central) · Cited by 11
Basu, A., Alman, A. C., & Snell‐Bergeon, J. K. (2021) · Nutrients · doi:10.3390/nu13031035 · Cited by 12
Mohammad, J. A., Fathi, Z. H., & Allwsh, T. A. (2021) · Pharmacia · doi:10.3897/pharmacia.68.e63449 · Cited by 11
“In addition, type 1 diabetic patients have 10-fold higher risk of cardiovascular mortality in comparison to general population (Lind et al. 2014).”
BackgroundDietary sodium intake relates to vascular health in children with type 1 diabetes
Anderson, J. J. A., Couper, J., Toome, S., Mpundu‐Kaambwa, C., Giles, L. C., Gent, R. J., Coppin, B., & Peña, A. S. (2017) · Pediatric Diabetes · doi:10.1111/pedi.12537 · Cited by 10
Uanini, N. (2001) · Anuario del Centro de Estudios Históricos "Prof. Carlos S. A. Segreti" · Cited by 10
Kang, Y. M., Giugliano, R. P., Ran, X., Deedwania, P., De Ferrari, G. M., George, J. T., Gouni-Berthold, I., Paiva da Silva Lima, G., Handelsman, Y., Lewis, B. S., et al. (2025) · Diabetes Care · doi:10.2337/dc25-0942 · Cited by 9
Sveen, K. A., Holte, K. B., Svanteson, M., Hanssen, K. F., Nilsson, J. Å., Bengtsson, E., & Berg, T. J. (2021) · Diabetes Care · doi:10.2337/dc20-2089 · Cited by 10
Serés‐Noriega, T., Ortega, E., Giménez, M., Perea, V., Boswell, L., Mariaca, K., Font, C., Mesa, A., Viñals, C., Blanco, J., et al. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.03.025 · Cited by 9
Hendrix, G., Lokhnygina, Y. V., Ramaker, M. E., Ilkayeva, O., Muehlbauer, M. J., Evans, W. J., Rasbach, L. E., Benjamin, R. S., Freemark, M., & Balikcioglu, P. G. (2023) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.448 · Cited by 9
Approach to Lipid Management in the Patient With Diabetes
Kim, S. J., & Subramanian, S. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf018 · Cited by 14
The Urgent Need for Breakthrough Therapies and a World Without Type 1 Diabetes
Starr, L., Dutta, S., Danne, T., Karpen, S. R., Hutton, C. T., & Kowalski, A. J. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01735-6 · Cited by 15
Eeg‐Olofsson, K., Nathanson, D., Spelman, T. D., Kyhlstedt, M., Seibold, A., Levrat‐Guillen, F., & Bolinder, J. (2025) · Diabetologia · doi:10.1007/s00125-025-06438-y · Cited by 12
“For individuals with type 1 diabetes and HbA 1c ≥82 mmol/mol (≥9.7%), this risk is estimated to be 8–10-fold [2].”
InfluentialVallivaara, H., Leppänen, H. A., Mustonen, J., Saari, A., Martikainen, J. A., & Rintamäki, R. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16520 · Cited by 10
Metadata
- Authors
- Lind, M., Svensson, A.-M., Kosiborod, M., Gudbjörnsdottir, S., Pivodic, A., Wedel, H., Dahlqvist, S., Clements, M., & Rosengren, A.
- Affiliations
- Children's Mercy Hospital (US)
- Region Västra Götaland (SE)
- Saint Luke's Hospital (US)
- Nordic School of Public Health (SE)
- Sahlgrenska University Hospital (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-11-20
- Volume
- 371
- Issue
- 21
- Pages
- 1972-1982
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2079297835
- Cited by
- 964
- References
- 31
- Citations by year
- 2026: 50 · 2025: 72 · 2024: 63 · 2023: 92 · 2022: 87 · 2021: 81 · 2020: 94 · 2019: 82 · 2018: 83 · 2017: 70 · 2016: 102 · 2015: 82 · 2014: 2
- FWCI
- 68.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Edwards Lifesciences
- Västra Götalandsregionen
- Regeneron Pharmaceuticals
- Dexcom
- Novo Nordisk
- Vetenskapsrådet ([2013-5187, 2013-4236])
- Svenska Läkaresällskapet
- Genentech
- Health and Medical Care Committee of the Regional Executive Board, Region Västra Götaland
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- type 1 diabetes, glycemic control, HbA1c, excess mortality, cardiovascular mortality, all-cause mortality, HbA1c thresholds, mortality risk, diabetes registry, Swedish National Diabetes Register, diabetes management guidelines, diabetes self-management education
- MeSH terms
- Adult, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Male, Middle Aged, Registries, Risk, Sweden, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.